Remove market-access video
article thumbnail

HCPs sound off on pharma marketing

World of DTC Marketing

We just finished talking to over 200 hundred HCPs about pharma marketing and salespeople to measure any differences since before the pandemic. Attitudes are indeed changing, but one need remains clear: access to data obtained during clinical and ongoing trials. Will they transform their HCP marketing or stick to dated models?

Marketing 218
article thumbnail

The Economics of Copay Accumulators, Maximizers, and Alternative Funding Programs (Video)

Drug Channels

In my most recent video webinar , I explored how plans and PBMs are turning to novel—and highly controversial—benefit design tools that access manufacturers’ patient support spending: copay accumulators, maximizers, and alternative funding programs. Click here if you can’t see the video below. d/b/a Drug Channels Institute.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Drug Channel Implications of the Inflation Reduction Act (NEW Live Video Webinar)

Drug Channels

Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s latest live video webinar: Drug Channel Implications of the Inflation Reduction Act This event will be broadcast live on Friday, April 5, 2024, from 12:00 p.m. This event is part of The Drug Channels 2024 Video Webinar Series.

Drugs 85
article thumbnail

Five Surprising Facts About GoodRx and the Discount Card Market (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I prepare for tomorrow’s live video webinar: Drug Channels Outlook 2023. The research was sponsored by the Association for Accessible Medicines (AAM). There’s a lot to unpack about the growing discount card market. Link below.) d/b/a Drug Channels Institute.

article thumbnail

The Economics of Copay Accumulators, Maximizers, and Alternative Funding Programs (Video) (rerun)

Drug Channels

In my most recent video webinar , I explored how plans and PBMs are turning to novel—and highly controversial—benefit design tools that access manufacturers’ patient support spending: copay accumulators, maximizers, and alternative funding programs. Click here if you can’t see the video below.

article thumbnail

California’s low-cost insulin plans receive $100m manufacturing boost

Pharmaceutical Technology

In a budget change proposed in February and confirmed in May , California’s Department of Health Care Access and Information (HCAI) requested a one-time investment of $100 million for Newsom’s CalRx Biosimilar Insulin initiative. Nothing epitomises market failures more than the cost of insulin,” Newsom said in a video posted on Twitter.

Insulin 328
article thumbnail

The potential of virtual reality-based therapy for serious mental disorders

Pharmaceutical Technology

The aim of the programme is to expedite the development, assessment and review of medical devices in order to provide timely access to patients and healthcare providers. According to GlobalData’s Epidemiology & Market Size database, around 1.2 million people in the UK and 2.7